FibroGen's sale to AstraZeneca is approved, set to close in Q3 2025, pending contractual conditions.
Quiver AI Summary
FibroGen, Inc. announced that the sale of FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited has been approved by the China State Administration for Market Regulation, with the transaction expected to close in the third quarter of 2025, pending other conditions. FibroGen is a biopharmaceutical company focused on developing therapies for cancer and anemia, with its product Roxadustat approved in multiple countries for treating anemia in chronic kidney disease patients. The company is also advancing FG-3246, a novel therapy for prostate cancer, and evaluating plans for Roxadustat in related conditions. The press release includes forward-looking statements about FibroGen’s strategies and prospects, with a caution for investors regarding the uncertainties associated with such statements.
Potential Positives
- Approval from the China State Administration for Market Regulation signifies regulatory affirmation of the company's strategic direction.
- The sale of FibroGen International to AstraZeneca is on track to close, potentially providing significant capital and strategic opportunities for the company.
- The ongoing development of Roxadustat and FG-3246 highlights the company's commitment to expanding its therapeutic offerings in significant healthcare markets.
Potential Negatives
- The company remains subject to contractual closing conditions and deliverables for the sale, which introduces uncertainty regarding the transaction's successful completion.
- Concerns about the progress and timing of its clinical programs may negatively impact investor confidence and perception of the company's future prospects.
- The need for continuous updates on forward-looking statements suggests potential volatility in company performance and risks associated with its ongoing clinical trials.
FAQ
What is the status of FibroGen's sale in China?
The sale of FibroGen International (Hong Kong) Ltd. to AstraZeneca is on track to close in the third quarter of 2025.
What approval has been received for the sale?
The China State Administration for Market Regulation has approved the sale of FibroGen International (Hong Kong) Ltd.
What is Roxadustat used for?
Roxadustat is approved for treating anemia in chronic kidney disease patients, both on dialysis and not on dialysis.
What clinical programs is FibroGen currently pursuing?
FibroGen is developing Roxadustat for lower-risk myelodysplastic syndrome and FG-3246 for metastatic castration-resistant prostate cancer.
Where can more information about FibroGen be found?
More information about FibroGen and its products can be found on their website at www.fibrogen.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$FGEN Insider Trading Activity
$FGEN insiders have traded $FGEN stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $FGEN stock by insiders over the last 6 months:
- JAMES A SCHOENECK has made 3 purchases buying 323,567 shares for an estimated $224,524 and 0 sales.
- THANE WETTIG (CEO) purchased 145,000 shares for an estimated $50,663
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$FGEN Hedge Fund Activity
We have seen 3 institutional investors add shares of $FGEN stock to their portfolio, and 52 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ASSENAGON ASSET MANAGEMENT S.A. removed 351,851 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,864,810
- VANGUARD GROUP INC removed 234,365 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,242,134
- PRIMECAP MANAGEMENT CO/CA/ removed 149,633 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $793,054
- BLACKROCK, INC. removed 94,893 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $502,932
- MARSHALL WACE, LLP removed 88,502 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $469,060
- 683 CAPITAL MANAGEMENT, LLC removed 85,536 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $662,690
- TWO SIGMA ADVISERS, LP removed 27,048 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $143,354
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$FGEN Analyst Ratings
Wall Street analysts have issued reports on $FGEN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 08/07/2025
To track analyst ratings and price targets for $FGEN, check out Quiver Quantitative's $FGEN forecast page.
$FGEN Price Targets
Multiple analysts have issued price targets for $FGEN recently. We have seen 2 analysts offer price targets for $FGEN in the last 6 months, with a median target of $146.5.
Here are some recent targets:
- Matthew Keller from HC Wainwright & Co. set a target price of $43.0 on 08/07/2025
Full Release
-
Sale of FibroGen China remains on track to close in 3Q 2025
SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the China State Administration for Market Regulation approved the sale of FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited, pursuant to the Share Purchase Agreement, dated February 20, 2025.
The closing of the transaction remains subject to other contractual closing conditions and deliverables and remains on track to close in the third quarter of 2025.
About FibroGen
FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (爱瑞卓
®
, EVRENZO™) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate a development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit
www.fibrogen.com
.
Forward-Looking Statements
This release contains forward-looking statements regarding FibroGen’s strategy, future plans and prospects, including statements regarding its commercial products and clinical programs. These forward-looking statements include, but are not limited to, statements regarding regulatory interactions, the closing of the sale of FibroGen China, and statements about FibroGen’s plans and objectives. These forward-looking statements are typically identified by use of terms such as “may,” “will”, “should,” “on track,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. FibroGen’s actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of its various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in FibroGen’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, each as filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and FibroGen undertakes no obligation to update any forward-looking statement in this press release, except as required by law.
For Investor Inquiries:
David DeLucia, CFA
Senior Vice President and Chief Financial Officer
[email protected]
